Achilles Therapeutics PLC ADR (NASDAQ:ACHL) is a biotechnology firm dedicated to developing next-generation, patient-specific therapies that target cancer. The company's innovative approach focuses on harnessing the power of T-cell therapies to treat solid tumors, aiming to create treatments that are more effective and personalized. Achilles Therapeutics is at the forefront of identifying and utilizing clonal neoantigens, which are unique to each tumor, to activate the immune system specifically against cancer cells, leaving healthy cells untouched. Their pipeline includes projects for various types of cancer, with objectives aimed at significantly improving patient outcomes. Through cutting-edge research and clinical trials, Achilles Therapeutics is committed to advancing the fight against cancer with personalized immunotherapies.